Go behind the scenes of LogiPharma USA 2026 with program director Charleen Ring and McKesson's Chris Van Norman in this Pharma Pulse special.
Commentary|Podcasts|March 29, 2024
A Further Examination of Pharmacy Benefit Managers
Author(s)Nicholas Saraceno, Senior Editor
Brandon Newman joins The Pharmaceutical Commerce Podcast to discuss the evolving role of PBMs, including the importance of drug price transparency.
Advertisement
In this exclusive PC Podcast interview, Brandon Newman, Xevant’s CEO and founder, explores:
- The implications of the Inflation Reduction Act’s price negotiation provisions, and how these could result in ripple effects across the healthcare system
- The role that pharmacy benefit managers (PBMs) and other intermediaries' play when it comes to determining drug costs, and how spread pricing is involved
- How Xevant helps improve drug cost transparency efforts
- Strategies for affordability Newman would offer the pharma industry that can be implemented immediately
The latest episode of The Pharmaceutical Commerce Podcast is available directly on
Advertisement
Related to this article
As HRSA's 340B Rebate Model Pilot moves toward its effective date, Valerie Bandy, PharmD, of Tecsys explains what drug-by-drug rebate tracking really demands from hospital and health system pharmacies.
Twenty-six manufacturers now hold most-favored-nation agreements, and the commitments attached to the pricing terms may matter more than the prices themselves.
Sponsored
Joe Reynolds, Head of User Experience Services at Noble, breaks down what it really takes for pharmaceutical companies to move therapy from the clinic into the patient's home.
Ed Schoonveld examines the uncertainty surrounding President Trump's MFN drug pricing agreements, stalled GENEROUS, GLOBE and GUARD proposals, and their ripple effects on ex-US drug launches.
In this week's Pharma Pulse, nine more drugmakers join the MFN program, GoodRx adds a family plan, IPC formalizes its USave partnership, and CSafe expands its thermal cover offerings.
The acquisition formalizes a nearly decade-old partnership as independent pharmacies lean on cooperatives to offset PBM reimbursement pressure and closures.
Nine more manufacturers join the MFN program, pairing new Medicaid pricing deals with $19.6B in U.S. manufacturing investment and API reserve donations.
Advertisement
Advertisement
Trending on Pharmaceutical Commerce
1
White House Extends MFN Pricing to Every State Medicaid Program
2
Pharma Pulse: Behind the Scenes of LogiPharma USA 2026
3
How Rebate Timing Distorts a Pharmacy's 340B Books
4
Pharma Pulse: Independent Pharmacies Sue Express Scripts, Novo Taps Anthropic, Pharma Joins Clean Heat
5